Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Jiuzhou Pharma Earmarks $42 Million for New CDMO Site in Japan

publication date: Jan 26, 2024

China's Jiuzhou Pharma will invest $42 million to expand its CDMO business by building a facility in Japan. Zhejiang Jiuzhou Pharma s a CDMO that evolved from a generic API company. The company’s CDMO subsidiary, Raybow Life Sciences, is headquartered in Singapore with facilities in China, the US and EU. It offers small molecule R&D and green chemical manufacturing. The parent company, Jiuzhou Pharma claims to be the top API global manufacturer and supplier of Carbamazepine, a treatment for seizures. Jiuzhou was founded in 1998 and is headquartered in Taizhou, Zhejiang Province. More details....

Stock Symbol: (SHA: 603456)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital